Starling Oncology (STLNW) Liabilities and Shareholders Equity (2019 - 2026)

Starling Oncology (STLNW) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $178.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 11.54% year-over-year to $178.2 million; the trailing twelve-month figure through Jun 2026 stood at $674.7 million (changed 0.14% YoY), and the FY2025 full-year result was $164.7 million, down 4.67% from the prior year.
• Liabilities and Shareholders Equity advanced to $178.2 million in Q2 2026 per STLNW's latest filing, from $168.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $283.8 million in Q3 2022 and bottomed at $159.8 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $198.2 million across 5 years, with a median of $184.7 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity climbed 28.62% in 2022, then dropped 23.06% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $261.7 million in 2022, then retreated by 20.04% to $209.2 million in 2023, then declined by 17.46% to $172.7 million in 2024, then slipped by 4.67% to $164.7 million in 2025, then climbed by 8.25% to $178.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $178.2 million, $168.2 million, and $164.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.